Kathy High, a gene therapy pioneer who led the development of a treatment for a form of blindness, has left the drug giant Roche just two months after it purchased the company she founded, Spark Therapeutics, for $4.3 billion.
Roche said in a statement Thursday that High would “take some well-deserved time off” and would “begin a new chapter in a sabbatical at a university.” Her departure was first reported by Philadelphia Business Journal.
About the Author Reprints
